GLP1R and alkaline phosphatase measurement: A recent meta-analysis reported a slightly increased risk of AP (relative risk: 1.44, 95% CI: 1.09-1.89; p = 0.009) with GLP-1 receptor agonists; however, this increased risk was not demonstrable when stratified by background medication use [45].